Axcella Health is a biotechnology company that researches and develops novel multifactorial interventions to support health and address dysregulated metabolism. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy, AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease, AXA2678 for use in treating immobilization-induced acute muscle atrophy, and AXA4010 to target multiple biological pathways.